NL1017075C2 - Preparaat. - Google Patents

Preparaat. Download PDF

Info

Publication number: NL1017075C2
Authority: NL; Netherlands
Prior art keywords: pharmaceutically acceptable; fulvestrant; preparation; pharmaceutical composition; less
Prior art date: 2000-01-10

Application number

NL1017075A

Other languages

English (en)

Dutch (nl)

Other versions

NL1017075A1 (nl

Inventor

John Raymond Evans

Rosalind Ursula Grundy

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-01-10

Filing date

2001-01-10

Publication date

2001-09-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26243352&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL1017075(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-01-10 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2001-07-11 Publication of NL1017075A1 publication Critical patent/NL1017075A1/xx

2001-09-25 Application granted granted Critical

2001-09-25 Publication of NL1017075C2 publication Critical patent/NL1017075C2/nl

Links

238000002360 preparation method Methods 0.000 title claims description 64
VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims description 85
229960002258 fulvestrant Drugs 0.000 claims description 85
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 71
239000000203 mixture Substances 0.000 claims description 54
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 45
SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical group C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 claims description 38
JBTWLSYIZRCDFO-UHFFFAOYSA-N ethyl methyl carbonate Chemical compound CCOC(=O)OC JBTWLSYIZRCDFO-UHFFFAOYSA-N 0.000 claims description 29
239000008194 pharmaceutical composition Substances 0.000 claims description 29
239000004359 castor oil Substances 0.000 claims description 24
235000019438 castor oil Nutrition 0.000 claims description 24
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 24
229940066675 ricinoleate Drugs 0.000 claims description 21
WBHHMMIMDMUBKC-QJWNTBNXSA-M ricinoleate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC([O-])=O WBHHMMIMDMUBKC-QJWNTBNXSA-M 0.000 claims description 21
238000002347 injection Methods 0.000 claims description 20
239000007924 injection Substances 0.000 claims description 20
229960002903 benzyl benzoate Drugs 0.000 claims description 19
235000019445 benzyl alcohol Nutrition 0.000 claims description 15
238000010255 intramuscular injection Methods 0.000 claims description 13
239000007927 intramuscular injection Substances 0.000 claims description 13
210000002381 plasma Anatomy 0.000 claims description 9
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
239000000825 pharmaceutical preparation Substances 0.000 claims description 5
210000000481 breast Anatomy 0.000 claims description 4
201000010099 disease Diseases 0.000 claims description 4
238000007918 intramuscular administration Methods 0.000 claims description 4
230000003211 malignant effect Effects 0.000 claims description 4
210000004994 reproductive system Anatomy 0.000 claims description 4
HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 3
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 claims description 3
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 claims description 3
229940093471 ethyl oleate Drugs 0.000 claims description 3
229940074928 isopropyl myristate Drugs 0.000 claims description 2
XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 claims description 2
229940075495 isopropyl palmitate Drugs 0.000 claims description 2
238000013160 medical therapy Methods 0.000 claims description 2
239000003921 oil Substances 0.000 description 17
235000019198 oils Nutrition 0.000 description 17
229960004756 ethanol Drugs 0.000 description 15
150000001875 compounds Chemical class 0.000 description 14
239000000328 estrogen antagonist Substances 0.000 description 12
230000001833 anti-estrogenic effect Effects 0.000 description 10
239000000262 estrogen Substances 0.000 description 10
229940046836 anti-estrogen Drugs 0.000 description 9
229940011871 estrogen Drugs 0.000 description 9
238000009472 formulation Methods 0.000 description 9
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 8
150000003431 steroids Chemical class 0.000 description 8
238000013268 sustained release Methods 0.000 description 8
239000012730 sustained-release form Substances 0.000 description 8
206010006187 Breast cancer Diseases 0.000 description 7
208000026310 Breast neoplasm Diseases 0.000 description 7
150000001298 alcohols Chemical class 0.000 description 7
102000015694 estrogen receptors Human genes 0.000 description 7
108010038795 estrogen receptors Proteins 0.000 description 7
-1 4,4,5,5,5-pentafluoropentylsulfinyl Chemical group 0.000 description 6
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
230000000694 effects Effects 0.000 description 6
239000000546 pharmaceutical excipient Substances 0.000 description 6
238000001556 precipitation Methods 0.000 description 6
239000000243 solution Substances 0.000 description 6
125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
239000002904 solvent Substances 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 4
239000003814 drug Substances 0.000 description 4
229960005309 estradiol Drugs 0.000 description 4
229930182833 estradiol Natural products 0.000 description 4
239000008159 sesame oil Substances 0.000 description 4
235000011803 sesame oil Nutrition 0.000 description 4
229960001603 tamoxifen Drugs 0.000 description 4
239000003981 vehicle Substances 0.000 description 4
229940079593 drug Drugs 0.000 description 3
239000003759 ester based solvent Substances 0.000 description 3
230000007794 irritation Effects 0.000 description 3
238000000034 method Methods 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
238000007911 parenteral administration Methods 0.000 description 3
230000003637 steroidlike Effects 0.000 description 3
239000004094 surface-active agent Substances 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
201000009273 Endometriosis Diseases 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
235000019483 Peanut oil Nutrition 0.000 description 2
241000700159 Rattus Species 0.000 description 2
230000009471 action Effects 0.000 description 2
230000037182 bone density Effects 0.000 description 2
239000013078 crystal Substances 0.000 description 2
STORWMDPIHOSMF-UHFFFAOYSA-N decanoic acid;octanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCC(O)=O.CCCCCCCCCC(O)=O STORWMDPIHOSMF-UHFFFAOYSA-N 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
230000001076 estrogenic effect Effects 0.000 description 2
238000001914 filtration Methods 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
239000000312 peanut oil Substances 0.000 description 2
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
230000000704 physical effect Effects 0.000 description 2
WBHHMMIMDMUBKC-XLNAKTSKSA-N ricinelaidic acid Chemical compound CCCCCC[C@@H](O)C\C=C\CCCCCCCC(O)=O WBHHMMIMDMUBKC-XLNAKTSKSA-N 0.000 description 2
229960003656 ricinoleic acid Drugs 0.000 description 2
FEUQNCSVHBHROZ-UHFFFAOYSA-N ricinoleic acid Natural products CCCCCCC(O[Si](C)(C)C)CC=CCCCCCCCC(=O)OC FEUQNCSVHBHROZ-UHFFFAOYSA-N 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
238000007789 sealing Methods 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000011877 solvent mixture Substances 0.000 description 2
150000003626 triacylglycerols Chemical class 0.000 description 2
230000001836 utereotrophic effect Effects 0.000 description 2
238000012371 Aseptic Filling Methods 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
241000282412 Homo Species 0.000 description 1
208000033830 Hot Flashes Diseases 0.000 description 1
206010060800 Hot flush Diseases 0.000 description 1
241001446467 Mama Species 0.000 description 1
206010027304 Menopausal symptoms Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241001191378 Moho Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
238000002679 ablation Methods 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000008484 agonism Effects 0.000 description 1
230000001270 agonistic effect Effects 0.000 description 1
125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
239000003886 aromatase inhibitor Substances 0.000 description 1
229940046844 aromatase inhibitors Drugs 0.000 description 1
MTZQAGJQAFMTAQ-UHFFFAOYSA-N benzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 description 1
229960004217 benzyl alcohol Drugs 0.000 description 1
230000008499 blood brain barrier function Effects 0.000 description 1
230000037058 blood plasma level Effects 0.000 description 1
210000001218 blood-brain barrier Anatomy 0.000 description 1
239000008364 bulk solution Substances 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
239000003086 colorant Substances 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
239000000470 constituent Substances 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
229960000935 dehydrated alcohol Drugs 0.000 description 1
239000003405 delayed action preparation Substances 0.000 description 1
238000013461 design Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
210000003746 feather Anatomy 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000002267 hypothalamic effect Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
239000003446 ligand Substances 0.000 description 1
150000002634 lipophilic molecules Chemical class 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000007774 longterm Effects 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
125000002958 pentadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
239000011148 porous material Substances 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
229940071643 prefilled syringe Drugs 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000003439 radiotherapeutic effect Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000008844 regulatory mechanism Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
230000007928 solubilization Effects 0.000 description 1
238000005063 solubilization Methods 0.000 description 1
239000012453 solvate Substances 0.000 description 1
238000000638 solvent extraction Methods 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000012360 testing method Methods 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
229960005026 toremifene Drugs 0.000 description 1
XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
230000001228 trophic effect Effects 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
238000011179 visual inspection Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Dermatology (AREA)
Diabetes (AREA)
Reproductive Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Steroid Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NL1017075A 2000-01-10 2001-01-10 Preparaat. NL1017075C2 (nl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GBGB0000313.7A GB0000313D0 (en)	2000-01-10	2000-01-10	Formulation
GB0000313		2000-01-10
GBGB0008837.7A GB0008837D0 (en)	2000-01-10	2000-04-12	Formulation
GB0008837		2000-04-12

Publications (2)

Publication Number	Publication Date
NL1017075A1 NL1017075A1 (nl)	2001-07-11
NL1017075C2 true NL1017075C2 (nl)	2001-09-25

Family

ID=26243352

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL1017075A NL1017075C2 (nl)	2000-01-10	2001-01-10	Preparaat.

Country Status (41)

Country	Link
US (5)	US20030125387A1 (pl)
EP (4)	EP2286818B1 (pl)
JP (3)	JP3713237B2 (pl)
KR (1)	KR100802366B1 (pl)
CN (1)	CN1222292C (pl)
AR (1)	AR027510A1 (pl)
AT (1)	ATE306928T1 (pl)
AU (1)	AU762080B2 (pl)
BE (1)	BE1013477A3 (pl)
BG (1)	BG65776B1 (pl)
BR (1)	BR0107445B1 (pl)
CA (1)	CA2351004C (pl)
CH (1)	CH696260A5 (pl)
CO (1)	CO5280206A1 (pl)
CY (1)	CY1116520T1 (pl)
CZ (1)	CZ304689B6 (pl)
DE (2)	DE60114145T3 (pl)
DK (2)	DK2266573T3 (pl)
EE (1)	EE05421B1 (pl)
EG (1)	EG24074A (pl)
ES (3)	ES2543384T3 (pl)
FR (1)	FR2803516B1 (pl)
GB (3)	GB0000313D0 (pl)
HK (2)	HK1049286B (pl)
HU (1)	HU230162B1 (pl)
IL (2)	IL150230A0 (pl)
IS (1)	IS2932B (pl)
IT (2)	ITTO20010005A1 (pl)
MX (1)	MXPA02006698A (pl)
MY (1)	MY118583A (pl)
NL (1)	NL1017075C2 (pl)
NO (2)	NO336286B1 (pl)
PL (1)	PL202525B1 (pl)
PT (2)	PT2266573E (pl)
RU (1)	RU2263507C9 (pl)
SI (2)	SI2266573T1 (pl)
SK (1)	SK287221B6 (pl)
TW (1)	TWI259086B (pl)
UA (1)	UA75879C2 (pl)
WO (1)	WO2001051056A1 (pl)
ZA (1)	ZA200204165B (pl)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0000313D0 (en) *	2000-01-10	2000-03-01	Astrazeneca Uk Ltd	Formulation
HUP0400115A3 (en) *	2001-07-07	2005-11-28	Astrazeneca Ab	Pharmaceutical composition for the intramuscular administration of fulvestrant
GB0116620D0 (en) *	2001-07-07	2001-08-29	Astrazeneca Ab	Formulation
EP1506286B1 (en) *	2002-05-24	2014-03-19	Merck Sharp & Dohme Corp.	Neutralizing human anti-igfr antibody
TW200404552A (en) *	2002-05-30	2004-04-01	Akzo Nobel Nv	Self administered contraception
US20050152858A1 (en) *	2003-07-11	2005-07-14	Isp Investments Inc.	Solubilizing agents for active or functional organic compounds
TW200526684A (en) *	2003-11-21	2005-08-16	Schering Corp	Anti-IGFR1 antibody therapeutic combinations
EP1623713A1 (en) *	2004-07-09	2006-02-08	Proskelia SAS	Cominations of pure anti-estrogen with aromatase inhibitors
JP4875064B2 (ja) *	2005-04-15	2012-02-15	シェーリングコーポレイション	癌を処置または予防するための方法および組成物
SG165404A1 (en) *	2005-09-26	2010-10-28	Hospira Australia Pty Ltd	Fulvestrant formulation
RU2338538C1 (ru) *	2007-02-09	2008-11-20	Государственное учебно-научное учреждение Химический факультет Московского государственного университета им. М.В. Ломоносова	Антигипотензивное средство
JP2011514349A (ja) *	2008-03-07	2011-05-06	サイドース・エルエルシー	フルベストラント配合物
AU2014200332B2 (en) *	2008-04-28	2016-10-06	Diurnal Limited	Lipid composition
GB0807605D0 (en) *	2008-04-28	2008-06-04	Diurnal Ltd	Lipid composition
UA104147C2 (uk) *	2008-09-10	2014-01-10	Новартис Аг	Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
US20100317635A1 (en)	2009-06-16	2010-12-16	Endorecherche, Inc.	Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
RS56042B1 (sr)	2010-06-10	2017-09-29	Seragon Pharmaceuticals Inc	Modulatori estrogenih receptora i njihove upotrebe
US8853423B2 (en)	2010-06-17	2014-10-07	Seragon Pharmaceuticals, Inc.	Indane estrogen receptor modulators and uses thereof
CA2811258C (en)	2010-09-16	2019-10-15	Shimoda Biotech (Pty) Ltd	Fulvestrant compositions and methods of use
ES2708302T3 (es) *	2011-05-20	2019-04-09	Capital Business Y Gestion De Finanzas S L	Composición farmacéutica
CN102391341B (zh) *	2011-08-09	2013-05-22	福建省微生物研究所	制备6,7-脱氢-17β-烃酰氧基诺龙的方法
CN103070871B (zh) *	2011-10-26	2015-04-15	正大天晴药业集团股份有限公司	一种氟维司群的药物组合物
US9301920B2 (en)	2012-06-18	2016-04-05	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
US8633178B2 (en)	2011-11-23	2014-01-21	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
WO2013090829A1 (en)	2011-12-14	2013-06-20	Aragon Pharmaceuticals, Inc.	Estrogen receptor modulators and uses thereof
EP2791128A4 (en)	2011-12-16	2015-04-22	Olema Pharmaceuticals Inc	NOVEL BENZOPYRAN COMPOUNDS, COMPOSITIONS AND USES THEREOF
CN102600073B (zh)	2012-03-31	2014-01-01	莱普德制药有限公司	以乳酸酯为基础的氟维司群或其衍生物油性制剂及其制备方法
CN102600064A (zh) *	2012-03-31	2012-07-25	西安力邦制药有限公司	氟维司群或其衍生物缓释制剂及其制备方法
ES2983451T3 (es) *	2012-04-09	2024-10-23	Eagle Pharmaceuticals Inc	Formulaciones de Fulvestrant
US11179468B2 (en)	2012-04-09	2021-11-23	Eagle Pharmaceuticals, Inc.	Fulvestrant formulations
US10806740B2 (en)	2012-06-18	2020-10-20	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
US20130338122A1 (en)	2012-06-18	2013-12-19	Therapeuticsmd, Inc.	Transdermal hormone replacement therapies
US10806697B2 (en)	2012-12-21	2020-10-20	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en)	2012-06-18	2015-07-16	Therapeuticsmd, Inc.	Progesterone formulations having a desirable pk profile
US10568891B2 (en)	2012-12-21	2020-02-25	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en)	2012-12-21	2020-01-21	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en)	2012-12-21	2019-11-12	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en)	2012-12-21	2015-11-10	Therapeuticsmd, Inc.	Soluble estradiol capsule for vaginal insertion
US11246875B2 (en)	2012-12-21	2022-02-15	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en)	2012-12-21	2022-03-08	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US20160060288A1 (en)	2013-04-18	2016-03-03	Xi'anlibang Pharmaceutical Technology Co., Ltd.	Ester derivatives of 7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)-estra-1,3,5(10)-triene-3,17beta-diol having anticancer activity and preparation method thereof
US10392667B2 (en)	2013-06-07	2019-08-27	Medical Prognosis Institute A/S	Methods and devices for predicting treatment efficacy of fulvestrant in cancer patients
WO2014203129A1 (en)	2013-06-19	2014-12-24	Olema Pharmaceuticals, Inc.	Combinations of benzopyran compounds, compositions and uses thereof
WO2014203132A1 (en)	2013-06-19	2014-12-24	Olema Pharmaceuticals, Inc.	Substituted benzopyran compounds, compositions and uses thereof
CN104337761B (zh) *	2013-08-07	2019-03-26	江苏豪森药业集团有限公司	氟维司群药物组合物
JP2016529308A (ja) *	2013-09-06	2016-09-23	サラーウッディンアハメド，	フルベストラント組成物
US9271990B2 (en)	2014-02-14	2016-03-01	Fresenius Kabi Usa, Llc	Fulvestrant formulations
WO2015136016A2 (en)	2014-03-13	2015-09-17	F. Hoffmann-La Roche Ag	Therapeutic combinations with estrogen receptor modulators
EP3145489A1 (en)	2014-05-22	2017-03-29	TherapeuticsMD, Inc.	Natural combination hormone replacement formulations and therapies
RU2016141135A (ru)	2014-07-29	2018-08-28	Терапьютиксмд, Инк.	Трансдермальный крем
TWI874834B (zh)	2014-12-18	2025-03-01	瑞士商赫孚孟拉羅股份公司	四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途
US10328087B2 (en)	2015-07-23	2019-06-25	Therapeuticsmd, Inc.	Formulations for solubilizing hormones
KR20240142622A (ko)	2015-10-01	2024-09-30	올레마 파마슈티컬스 인코포레이티드	테트라히드로-1H-피리도[3,4-b]인돌 항에스트로겐 약물
US20180289721A1 (en)	2015-10-13	2018-10-11	Themis Medicare Limited	Fulvestrant compositions
LT3386500T (lt)	2015-12-09	2022-12-27	The Board Of Trustees Of The University Of Illinois	Selektyvūs estrogenų receptorių slopintojai benzotiofeno pagrindu
WO2017173071A1 (en)	2016-04-01	2017-10-05	Therapeuticsmd, Inc.	Steroid hormone pharmaceutical composition
WO2017173044A1 (en)	2016-04-01	2017-10-05	Therapeuticsmd Inc.	Steroid hormone compositions in medium chain oils
WO2017175810A1 (ja) *	2016-04-06	2017-10-12	富士フイルム株式会社	医薬組成物
EP3440067B1 (en)	2016-04-08	2021-05-26	F. Hoffmann-La Roche AG	Tetrahydroisoquinoline estrogen receptor modulators and uses thereof
IL285928B2 (en) *	2016-05-06	2025-06-01	Eagle Pharmaceuticals Inc	Fulvestrant formulations and methods of their use
US11590077B2 (en)	2016-05-06	2023-02-28	Eagle Pharmaceuticals, Inc.	Fulvestrant formulations and methods of their use
WO2017208847A1 (ja) *	2016-05-31	2017-12-07	富士フイルム株式会社	医薬組成物
US20180002344A1 (en)	2016-06-16	2018-01-04	Genentech, Inc.	Heteroaryl estrogen receptor modulators and uses thereof
CN109843882A (zh)	2016-06-16	2019-06-04	豪夫迈·罗氏有限公司	四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
EP3472162B1 (en) *	2016-06-16	2021-11-17	F. Hoffmann-La Roche AG	Heteroaryl estrogen receptor modulators and uses thereof
CN107789320B (zh) *	2016-08-31	2021-06-22	鲁南制药集团股份有限公司	一种氟维司群缓释注射液及其制备工艺
IL304863B2 (en)	2017-09-11	2025-08-01	Atossa Therapeutics Inc	Methods for making and using endoxifen
JP7220712B2 (ja) *	2017-11-08	2023-02-10	イーグルファーマスーティカルズ、インク．	フルベストラント製剤とその使用方法
CN111655288A (zh)	2017-11-16	2020-09-11	诺华股份有限公司	组合疗法
WO2019151353A1 (ja) *	2018-01-31	2019-08-08	富士フイルム株式会社	注射用製剤の製造方法
RU2684330C1 (ru) *	2018-02-02	2019-04-08	Закрытое Акционерное Общество "Биокад"	Композиции фулвестранта
JP7384903B2 (ja)	2018-05-24	2023-11-21	ケーアイファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー	フルベストラントのプロドラッグ
AR116109A1 (es)	2018-07-10	2021-03-31	Novartis Ag	Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
CN111035613A (zh) *	2018-10-12	2020-04-21	江苏恒瑞医药股份有限公司	一种包含氟维司群的可注射的药物组合物及其制备方法
CR20210287A (es)	2018-11-01	2022-02-15	Syros Pharmaceuticals Inc	Inhibidores de cinasa 7 dependiente de ciclina (cdk7)
KR20210106437A (ko)	2018-12-20	2021-08-30	노파르티스 아게	3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
CA3123519A1 (en)	2019-02-15	2020-08-20	Novartis Ag	Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CN113490528B (zh)	2019-02-15	2024-12-03	诺华股份有限公司	3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
KR20220024106A (ko)	2019-05-20	2022-03-03	노파르티스 아게	Mcl-1 억제제 항체-약물 접합체 및 사용 방법
JP7662204B2 (ja)	2019-07-03	2025-04-15	アトッサ・セラピューティクス・インコーポレイテッド	エンドキシフェンの徐放性組成物
KR20220034129A (ko)	2019-07-07	2022-03-17	올레마 파마슈티컬스 인코포레이티드	에스트로겐 수용체 길항제 요법
RU2722988C1 (ru) *	2019-11-19	2020-06-05	федеральное государственное бюджетное образовательное учреждение высшего образования "Башкирский государственный медицинский университет" Министерства здравоохранения Российской Федерации	Способ моделирования проканцерогенного действия фулвестранта на яичники потомства женского пола у лабораторных мышей
EP4074304A4 (en) *	2019-12-11	2024-01-10	Shanghai Bocimed Pharmaceutical Co., Ltd.	PHARMACEUTICAL COMPOSITION OF FULVESTRANT, PREPARATION METHOD AND APPLICATION THEREOF
BR112022011902A2 (pt)	2019-12-20	2022-09-06	Novartis Ag	Terapias de combinação
US11633405B2 (en)	2020-02-07	2023-04-25	Therapeuticsmd, Inc.	Steroid hormone pharmaceutical formulations
KR20230027056A (ko)	2020-06-23	2023-02-27	노파르티스 아게	3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법
JP7819176B2 (ja)	2020-08-03	2026-02-24	ノバルティスアーゲー	ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
PE20240225A1 (es)	2020-11-24	2024-02-16	Novartis Ag	Anticuerpos anti-cd48, conjugados de anticuerpo-farmaco, y usos de los mismos
IL303079A (en)	2020-11-24	2023-07-01	Novartis Ag	Mcl-1 inhibitor antibody-drug conjugates and methods of use
JP2024505562A (ja)	2021-02-02	2024-02-06	レスラボラトイレスセルビエル	選択的ｂｃｌ－ｘｌｐｒｏｔａｃ化合物及び使用の方法
TW202304979A (zh)	2021-04-07	2023-02-01	瑞士商諾華公司	抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AR125874A1 (es)	2021-05-18	2023-08-23	Novartis Ag	Terapias de combinación
KR20230094172A (ko) *	2021-12-20	2023-06-27	주식회사 삼양홀딩스	용해도가 개선된 풀베스트란트의 약학 조성물 및 그 제조 방법
AU2023271885A1 (en)	2022-05-20	2024-12-12	Les Laboratoires Servier	Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
CN119562832A (zh)	2022-05-20	2025-03-04	诺华股份有限公司	Met bcl-xl抑制剂抗体-药物缀合物及其使用方法
AU2024234194A1 (en)	2023-03-10	2025-08-07	Novartis Ag	Panras inhibitor antibody-drug conjugates and methods of use thereof
PY24103486A (es)	2023-11-22	2025-06-06	Servier Lab	Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos
WO2025215536A1 (en)	2024-04-10	2025-10-16	Novartis Ag	Macrocyclic panras inhibitors for the treatment of cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0346014A1 (en) *	1988-06-06	1989-12-13	Zeneca Limited	Therapeutic product for the treatment of peri- or postmenopausal conditions
WO1996019997A1 (de) *	1994-12-23	1996-07-04	Schering Aktiengesellschaft	Progesteronantagonistisch- und antiöstrogen wirksame verbindungen zur gemeinsamen verwendung für die weibliche kontrazeption
WO1997021440A1 (en) *	1995-12-12	1997-06-19	Zeneca Limited	A solution for oral administration containing ici 182,780

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB817241A (en)	1957-08-21	1959-07-29	Vismara Francesco Spa	Oily solutions for parenteral administration containing adreno-cortical hormones
FR6241E (fr)	1905-04-19	1906-10-10	Ktiengesellschaft	Système de refroidissement du piston des moteurs à explosions et des compresseurs
DE947335C (de)	1954-10-19	1956-08-16	Schering Ag	Verfahren zur Herstellung stabiler oeliger Loesungen von Oestron
US2983649A (en)	1957-10-15	1961-05-09	Francesco Vismara Societa Per	Ricinoleic acid ester solutions of adreno-cortical hormones
GB1060632A (en) *	1962-09-11	1967-03-08	Olin Mathieson	Steroid compositions
US3164520A (en) †	1962-10-29	1965-01-05	Olin Mathieson	Injectable steroid compositions containing at least 75% benzyl benzoate
JPS4327327Y1 (pl)	1965-01-07	1968-11-12
NL151903B (nl)	1965-03-24	1977-01-17	Schering Ag	Werkwijze ter bereiding van een injectievloeistof door een steroid op te lossen in een mengsel van ricinusolie en benzylbenzoaat.
USRE28690E (en) *	1965-05-05	1976-01-20	Schering Aktiengesellschaft	17α-Ethinyl-18-methyl-19-nortestosterone esters
GB1207571A (en) *	1967-01-13	1970-10-07	Takeda Chemical Industries Ltd	Injectable composition
SU549118A1 (ru)	1973-04-02	1977-03-05		Способ синхронизации половой охоты у циклирующих свиноматок
SU676284A1 (ru)	1975-06-26	1979-07-30	Научно-Исследовательский Институт Животноводства	Способ синхронизации половой охоты у самок домашних животных
DE2548413A1 (de)	1975-10-27	1977-04-28	Schering Ag	Depotpraeparate in oeliger ungesaettigter loesung zur intramuskulaeren injektion
US4048310A (en)	1976-02-24	1977-09-13	E. R. Squibb & Sons, Inc.	Topical steroid formulation in form of lotion or cream
US4048309A (en)	1976-02-24	1977-09-13	E. R. Squibb & Sons, Inc.	Topical steroid ointment formulations
NL7711916A (nl)	1977-10-29	1979-05-02	Akzo Nv	Werkwijze ter bereiding van sterk geconcen- treerde farmaceutische preparaten van steroiden.
DE2907460A1 (de) *	1978-03-07	1979-09-13	Sandoz Ag	Neue resorbierbare galenische kompositionen
GB8327256D0 (en)	1983-10-12	1983-11-16	Ici Plc	Steroid derivatives
DE3708942A1 (de)	1987-03-18	1988-09-29	Schering Ag	19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3733478A1 (de)	1987-10-01	1989-04-13	Schering Ag	Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore
EP0310542B1 (de) †	1987-10-01	1994-06-08	Schering Aktiengesellschaft	Antigestagen- und antiöstrogenwirksame Verbindungen zur Behandlung hormonabhängiger Tumoren
JPH04327327A (ja)	1991-04-25	1992-11-16	Toyoda Gosei Co Ltd	スリーブとホースの加締め用ダイス
CN1102095A (zh)	1993-10-30	1995-05-03	浙江医科大学	长效雄激素类制剂——十一酸睾丸注射液
IL111991A (en)	1994-01-28	2000-07-26	Abbott Lab	Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
DE19510861A1 (de)	1995-03-16	1996-09-19	Schering Ag	Einmonatsspritze als Depot-Kontrazeptivum und für die Hormonersatztherapie für peri- und praemenopausale Frauen
US20010006963A1 (en)	1995-03-16	2001-07-05	Ursula Lachnit-Fixson	Once-a-month injection as a depot contraceptive and for hormone replacement therapy for perimenopausal and premenopausal women
EP0760237A1 (en)	1995-08-30	1997-03-05	Cipla Limited	Oil-in-water microemulsions
JPH09208496A (ja) *	1996-01-30	1997-08-12	Takeda Chem Ind Ltd	Ｌｈ−ｒｈ拮抗物質含有組成物
DE19613972A1 (de)	1996-04-09	1997-10-16	Bayer Ag	Injektionsformulierungen von Avermectinen und Milbemycinen auf Basis von Rizinusöl
GB9608719D0 (en)	1996-04-26	1996-07-03	Scherer Ltd R P	Pharmaceutical compositions
KR980008226A (ko)	1996-07-05	1998-04-30	다케다 쿠니오	시각기능장애의 예방 및 치료제
JPH10203982A (ja) *	1996-07-05	1998-08-04	Takeda Chem Ind Ltd	視機能障害の予防・治療剤
DE19635525A1 (de) *	1996-08-20	1998-02-26	Schering Ag	7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
DE19638045A1 (de)	1996-09-18	1998-03-19	Bayer Ag	Injektionsformulierungen von Avermectinen und Milbemycinen
JPH10152438A (ja) *	1996-11-22	1998-06-09	Takeda Chem Ind Ltd	１−アザキサントン誘導体またはその塩の安定化方法および１−アザキサントン誘導体含有組成物
US6191107B1 (en)	1997-09-26	2001-02-20	Takeda Chemical Industries, Ltd.	Complex of human growth hormone and zinc
JPH11158200A (ja) *	1997-09-26	1999-06-15	Takeda Chem Ind Ltd	ヒト成長ホルモン・亜鉛複合体及びその用途
ME00855B (me)	1997-12-03	2008-08-07	Merck & Co Inc	Injektibilne formulacije dugog dejstva koje sadrže hidrogenisano ricinusovo ulje
WO2000059473A1 (en)	1999-04-01	2000-10-12	Inex Pharmaceuticals Corp.	Compositions and methods for treating lymphoma
GB0000313D0 (en)	2000-01-10	2000-03-01	Astrazeneca Uk Ltd	Formulation
JP4327327B2 (ja)	2000-04-03	2009-09-09	ロボテック株式会社	固定スプレー揺動装置
HUP0400115A3 (en)	2001-07-07	2005-11-28	Astrazeneca Ab	Pharmaceutical composition for the intramuscular administration of fulvestrant
GB0912999D0 (en)	2009-07-27	2009-09-02	Astrazeneca Ab	Method-803

2000
- 2000-01-10 GB GBGB0000313.7A patent/GB0000313D0/en not_active Ceased
- 2000-04-12 GB GBGB0008837.7A patent/GB0008837D0/en not_active Ceased
2001
- 2001-01-08 HK HK03101532.0A patent/HK1049286B/en not_active IP Right Cessation
- 2001-01-08 HU HU0204137A patent/HU230162B1/hu not_active IP Right Cessation
- 2001-01-08 IL IL15023001A patent/IL150230A0/xx active IP Right Grant
- 2001-01-08 CN CNB018035469A patent/CN1222292C/zh not_active Ceased
- 2001-01-08 US US10/169,777 patent/US20030125387A1/en not_active Abandoned
- 2001-01-08 WO PCT/GB2001/000049 patent/WO2001051056A1/en not_active Ceased
- 2001-01-08 PT PT101806677T patent/PT2266573E/pt unknown
- 2001-01-08 DK DK10180667.7T patent/DK2266573T3/en active
- 2001-01-08 EP EP10180661.0A patent/EP2286818B1/en not_active Expired - Lifetime
- 2001-01-08 BR BRPI0107445-8A patent/BR0107445B1/pt active IP Right Grant
- 2001-01-08 DK DK01900186.6T patent/DK1250138T4/en active
- 2001-01-08 EP EP10180667.7A patent/EP2266573B1/en not_active Expired - Lifetime
- 2001-01-08 AT AT01900186T patent/ATE306928T1/de active
- 2001-01-08 EP EP05016921A patent/EP1669073A3/en not_active Withdrawn
- 2001-01-08 MX MXPA02006698A patent/MXPA02006698A/es active IP Right Grant
- 2001-01-08 CZ CZ2002-2384A patent/CZ304689B6/cs not_active IP Right Cessation
- 2001-01-08 SK SK984-2002A patent/SK287221B6/sk not_active IP Right Cessation
- 2001-01-08 PL PL356030A patent/PL202525B1/pl unknown
- 2001-01-08 HK HK03105241.3A patent/HK1052884B/zh not_active IP Right Cessation
- 2001-01-08 ES ES10180667.7T patent/ES2543384T3/es not_active Expired - Lifetime
- 2001-01-08 ES ES01900186.6T patent/ES2248272T5/es not_active Expired - Lifetime
- 2001-01-08 EG EG20010017A patent/EG24074A/xx active
- 2001-01-08 KR KR1020027008855A patent/KR100802366B1/ko not_active Expired - Lifetime
- 2001-01-08 RU RU2002121507A patent/RU2263507C9/ru active
- 2001-01-08 JP JP2001551480A patent/JP3713237B2/ja not_active Expired - Lifetime
- 2001-01-08 EE EEP200200387A patent/EE05421B1/xx unknown
- 2001-01-08 SI SI200131044T patent/SI2266573T1/sl unknown
- 2001-01-08 CA CA002351004A patent/CA2351004C/en not_active Expired - Fee Related
- 2001-01-08 DE DE60114145.8T patent/DE60114145T3/de not_active Expired - Lifetime
- 2001-01-08 SI SI200130446T patent/SI1250138T2/sl unknown
- 2001-01-08 AU AU23863/01A patent/AU762080B2/en not_active Expired
- 2001-01-08 EP EP01900186.6A patent/EP1250138B2/en not_active Expired - Lifetime
- 2001-01-08 GB GB0100407A patent/GB2359254B/en not_active Expired - Lifetime
- 2001-01-09 BE BE2001/0021A patent/BE1013477A3/fr not_active IP Right Cessation
- 2001-01-09 US US09/756,291 patent/US6774122B2/en not_active Expired - Lifetime
- 2001-01-09 IT IT000005A patent/ITTO20010005A1/it unknown
- 2001-01-09 PT PT102548A patent/PT102548A/pt not_active Application Discontinuation
- 2001-01-10 IT IT2001TO000008A patent/ITTO20010008A1/it unknown
- 2001-01-10 TW TW090100514A patent/TWI259086B/zh not_active IP Right Cessation
- 2001-01-10 MY MYPI20010107A patent/MY118583A/en unknown
- 2001-01-10 ES ES200100057A patent/ES2186517B2/es not_active Expired - Fee Related
- 2001-01-10 AR ARP010100100A patent/AR027510A1/es not_active Application Discontinuation
- 2001-01-10 NL NL1017075A patent/NL1017075C2/nl not_active IP Right Cessation
- 2001-01-10 DE DE10100779A patent/DE10100779A1/de not_active Ceased
- 2001-01-10 CH CH00029/01A patent/CH696260A5/de not_active IP Right Cessation
- 2001-01-10 FR FR0100248A patent/FR2803516B1/fr not_active Expired - Lifetime
- 2001-01-10 CO CO01001317A patent/CO5280206A1/es not_active Application Discontinuation
- 2001-08-01 UA UA2002086628A patent/UA75879C2/uk unknown
2002
- 2002-05-24 ZA ZA200204165A patent/ZA200204165B/xx unknown
- 2002-06-13 IL IL150230A patent/IL150230A/en unknown
- 2002-06-18 BG BG106833A patent/BG65776B1/bg unknown
- 2002-07-03 IS IS6454A patent/IS2932B/is unknown
- 2002-07-03 NO NO20023227A patent/NO336286B1/no not_active IP Right Cessation
2003
- 2003-10-23 JP JP2003362875A patent/JP2004107353A/ja not_active Ceased
2004
- 2004-06-22 US US10/872,784 patent/US7456160B2/en not_active Expired - Lifetime
2008
- 2008-10-15 US US12/285,887 patent/US8329680B2/en not_active Expired - Fee Related
2011
- 2011-06-20 JP JP2011135962A patent/JP2011190275A/ja active Pending
2012
- 2012-09-04 US US13/602,667 patent/US8466139B2/en not_active Expired - Fee Related
2015
- 2015-06-08 NO NO20150741A patent/NO337329B1/no not_active IP Right Cessation
- 2015-07-22 CY CY20151100648T patent/CY1116520T1/el unknown

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0346014A1 (en) *	1988-06-06	1989-12-13	Zeneca Limited	Therapeutic product for the treatment of peri- or postmenopausal conditions
WO1996019997A1 (de) *	1994-12-23	1996-07-04	Schering Aktiengesellschaft	Progesteronantagonistisch- und antiöstrogen wirksame verbindungen zur gemeinsamen verwendung für die weibliche kontrazeption
WO1997021440A1 (en) *	1995-12-12	1997-06-19	Zeneca Limited	A solution for oral administration containing ici 182,780

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JOHN C. WATERTON; ET AL.: "A Case of Adenomyosis in a Pigtailed Monkey Diagnosed by Magnetic Resonance Imaging and treated with the Novel Pure Antiestrogen, ICI 182,780", LABORATORY ANIMAL SCIENCE, vol. 43, no. 3, 1993, pages 247 - 251, XP000998289 *

Also Published As

Publication number	Publication date
HK1049286B (en)	2006-04-07
GB2359254B (en)	2002-06-19
EP1250138B1 (en)	2005-10-19
BE1013477A3 (fr)	2002-02-05
ATE306928T1 (de)	2005-11-15
NO336286B1 (no)	2015-07-13
US20010020016A1 (en)	2001-09-06
BR0107445A (pt)	2002-09-17
US8466139B2 (en)	2013-06-18
CA2351004C (en)	2003-02-18
EP2266573A1 (en)	2010-12-29
FR2803516B1 (fr)	2003-03-28
IS6454A (is)	2002-07-03
ES2543384T3 (es)	2015-08-18
CA2351004A1 (en)	2001-07-10
MY118583A (en)	2004-12-31
CZ304689B6 (cs)	2014-09-03
EE05421B1 (et)	2011-06-15
HK1150021A1 (en)	2011-10-28
NO20150741L (no)	2002-07-03
NO337329B1 (no)	2016-03-14
US20100152149A1 (en)	2010-06-17
ITTO20010005A1 (it)	2001-07-11
BG106833A (en)	2003-03-31
DK1250138T4 (en)	2015-07-27
ES2248272T5 (es)	2015-08-19
CN1394141A (zh)	2003-01-29
SK9842002A3 (en)	2003-05-02
EP2266573B1 (en)	2015-06-17
ES2248272T3 (es)	2006-03-16
BR0107445B1 (pt)	2012-10-30
PT102548A (pt)	2001-07-31
US20120329766A1 (en)	2012-12-27
CH696260A5 (de)	2007-03-15
CO5280206A1 (es)	2003-05-30
US20030125387A1 (en)	2003-07-03
JP2003519659A (ja)	2003-06-24
CN1222292C (zh)	2005-10-12
US6774122B2 (en)	2004-08-10
IL150230A0 (en)	2002-12-01
KR20020073499A (ko)	2002-09-26
AU2386301A (en)	2001-07-24
JP3713237B2 (ja)	2005-11-09
KR100802366B1 (ko)	2008-02-13
EP2286818B1 (en)	2020-03-18
DK1250138T3 (da)	2006-01-23
RU2263507C2 (ru)	2005-11-10
ES2186517B2 (es)	2004-03-16
HU230162B1 (hu)	2015-09-28
US8329680B2 (en)	2012-12-11
GB0008837D0 (en)	2000-05-31
PL202525B1 (pl)	2009-07-31
EP1250138B2 (en)	2015-07-08
DE60114145D1 (de)	2006-03-02
HK1049286A1 (en)	2003-05-09
HK1052884A1 (en)	2003-10-03
ITTO20010005A0 (it)	2001-01-09
ITTO20010008A0 (it)	2001-01-10
PT2266573E (pt)	2015-07-28
HUP0204137A3 (en)	2005-03-29
HK1052884B (zh)	2006-07-14
RU2263507C9 (ru)	2020-07-28
SK287221B6 (sk)	2010-03-08
ITTO20010008A1 (it)	2002-07-10
PL356030A1 (pl)	2004-06-14
AR027510A1 (es)	2003-04-02
ZA200204165B (en)	2003-10-29
MXPA02006698A (es)	2002-09-30
FR2803516A1 (fr)	2001-07-13
TWI259086B (en)	2006-08-01
GB2359254A (en)	2001-08-22
GB0100407D0 (en)	2001-02-21
EG24074A (en)	2008-05-11
AU762080B2 (en)	2003-06-19
DE60114145T3 (de)	2015-09-17
BG65776B1 (bg)	2009-11-30
IL150230A (en)	2006-10-31
DK2266573T3 (en)	2015-07-20
WO2001051056A1 (en)	2001-07-19
UA75879C2 (en)	2006-06-15
EP1669073A3 (en)	2008-03-19
US20050043285A1 (en)	2005-02-24
ES2186517A1 (es)	2003-05-01
SI1250138T2 (sl)	2015-09-30
CY1116520T1 (el)	2017-03-15
EP1250138A1 (en)	2002-10-23
DE10100779A1 (de)	2001-07-26
RU2002121507A (ru)	2004-03-20
EE200200387A (et)	2003-10-15
IS2932B (is)	2015-12-15
HUP0204137A2 (hu)	2003-04-28
EP2286818A1 (en)	2011-02-23
GB0000313D0 (en)	2000-03-01
JP2004107353A (ja)	2004-04-08
NL1017075A1 (nl)	2001-07-11
EP1669073A2 (en)	2006-06-14
SI2266573T1 (sl)	2015-08-31
NO20023227L (no)	2002-07-03
US7456160B2 (en)	2008-11-25
DE60114145T2 (de)	2006-07-13
CZ20022384A3 (cs)	2002-09-11
JP2011190275A (ja)	2011-09-29
SI1250138T1 (sl)	2006-02-28
NO20023227D0 (no)	2002-07-03

Legal Events

Date	Code	Title	Description
2001-09-03	AD1B	A search report has been drawn up
2001-12-03	PD2B	A search report has been drawn up
2019-09-04	MM	Lapsed because of non-payment of the annual fee	Effective date: 20190201

Publication	Publication Date	Title
NL1017075C2 (nl)	2001-09-25	Preparaat.
KR20040010841A (ko)	2004-01-31	풀베스트란트의 근육내 주사용 약학 제제
HK1150021B (en)	2016-04-01	Fulvestrant formulation
HK1153393A (en)	2012-03-30	Fulvestrant formulation